Roman GALETTO,Agnes GOUBLE,Stephanie GROSSE,Cécile SCHIFFER-MANNIOUI,Laurent POIROT,Andrew SCHARENBERG,Julianne SMITH
申请号：
US14894426
公开号：
US20160120906A1
申请日:
2014.05.13
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.
